Bionomics begins manufacture of anti-cancer stem cell treatment

04/25/2013 | Pharmaceutical Business Review Online

Bionomics has begun production work for BNC101, its stem cell therapy candidate for cancer, at its U.K. plant in Slough. "The start of manufacturing activities for BNC101 signals a significant step towards clinical trials," said Bionomics' CEO and managing director, Deborah Rathjen. The firm expects clinical studies to start next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA